Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Veit Bücklein, Tina Adunka, Anna N. Mendler, Rolf Issels, Marion Subklewe, Jan C. Schmollinger & Elfriede Noessner. (2016) Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. OncoImmunology 5:7.
Read now
Read now
Karin Jöhrer, Sebastian W Hofbauer, Claudia Zelle-Rieser, Richard Greil & Tanja N Hartmann. (2012) Chemokine-dependent B cell–T cell interactions in chronic lymphocytic leukemia and multiple myeloma – targets for therapeutic intervention?. Expert Opinion on Biological Therapy 12:4, pages 425-441.
Read now
Read now
John C. Byrd, Bercedis L. Peterson, Kanti R. Rai, David Hurd, Raymond Hohl, Michael C. Perry, Jon Gockerman, Sreenivasa Nattam & Richard A. Larson. (2009) Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia & Lymphoma 50:10, pages 1589-1596.
Read now
Read now
Tait Shanafelt & Neil Kay. (2006) T-cell abnormalities in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 47:7, pages 1197-1198.
Read now
Read now
Articles from other publishers (6)
Reem Karmali, Laura A Paganessi, Robin R Frank, Sucheta Jagan, Melissa L Larson, Parameswaran Venugopal, Stephanie A Gregory & Kent W Christopherson. (2013) Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. Journal of Leukocyte Biology 93:1, pages 161-170.
Crossref
Crossref
Shahryar Kiaii, Parviz Kokhaei, Fariba Mozaffari, Eva Rossmann, Fatemeh Pak, Ali Moshfegh, Marzia Palma, Lotta Hansson, Kaveh Mashayekhi, Mohammad Hojjat-Farsangi, Anders Österborg, Aniruddha Choudhury & Håkan Mellstedt. (2012) T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile. Cancer Immunology, Immunotherapy 62:1, pages 51-63.
Crossref
Crossref
Iwona Urbanowicz, Grzegorz Mazur, Jolanta Stacherzak-Pawlik, Katarzyna Bogunia-Kubik, Tomasz Wróbel, Mieczysław Woźniak & Kazimierz Kuliczkowski. (2009) IFN Gamma Gene Polymorphism May Contribute to the Susceptibility to CLL. Pathology & Oncology Research 16:2, pages 213-216.
Crossref
Crossref
Yuri Souwer, Martine E. D. Chamuleau, Arjan A. van de Loosdrecht, Eva Tolosa, Tineke Jorritsma, Jettie J. F. Muris, Marion J. Dinnissen-van Poppel, Sander N. Snel, Lisette van de Corput, Gert J. Ossenkoppele, Chris J. L. M. Meijer, Jacques J. Neefjes & S. Marieke van Ham. (2009)
Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies
HLA-DOA
mRNA as a prognostic factor for survival
. British Journal of Haematology 145:3, pages 334-343.
Crossref
Crossref
Anders Österborg, Claes Karlsson & Jeanette Lundin. (2008) Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports 4:1, pages 47-53.
Crossref
Crossref
Mohammad Reza Rezvany, Mahmood Jeddi Tehrani, Claes Karlsson, Jeanette Lundin, Hodjattallah Rabbani, Anders Österborg & Håkan Mellstedt. (2006) Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. British Journal of Haematology 135:4, pages 475-485.
Crossref
Crossref